NasdaqGS - Nasdaq Real Time Price USD
Olema Pharmaceuticals, Inc. (OLMA)
As of 10:10 AM EDT. Market Open.
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 7 | 7 | 7 |
| Avg. Estimate | -0.58 | -0.63 | -2.33 | -2.62 |
| Low Estimate | -0.63 | -0.72 | -2.45 | -2.93 |
| High Estimate | -0.5 | -0.55 | -2.19 | -2.22 |
| Year Ago EPS | -0.48 | -0.49 | -2.14 | -2.33 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 6 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.51 | -0.48 | -0.55 | -0.55 |
| EPS Actual | -0.48 | -0.49 | -0.56 | -0.54 |
| Difference | 0.03 | -0.01 | -0.01 | 0.01 |
| Surprise % | 5.90% | -2.10% | -1.80% | 1.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.58 | -0.63 | -2.33 | -2.62 |
| 7 Days Ago | -0.58 | -0.63 | -2.33 | -2.62 |
| 30 Days Ago | -0.58 | -0.63 | -2.33 | -2.62 |
| 60 Days Ago | -0.58 | -0.63 | -2.32 | -2.56 |
| 90 Days Ago | -0.58 | -0.64 | -2.36 | -2.57 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | OLMA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -20.80% | -- | -- | 4.40% |
| Next Qtr. | -28.60% | -- | -- | 7.80% |
| Current Year | -8.90% | -- | -- | 2.50% |
| Next Year | -12.40% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.89% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Maintains | JP Morgan: Overweight to Overweight | 8/8/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/7/2024 |
| Reiterates | Oppenheimer: Outperform to Outperform | 8/7/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 6/4/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/15/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 5/9/2024 |
Related Tickers
MLYS Mineralys Therapeutics, Inc.
13.67
-0.22%
ORIC ORIC Pharmaceuticals, Inc.
9.71
+2.00%
SYRE Spyre Therapeutics, Inc.
31.20
-0.89%
LYEL Lyell Immunopharma, Inc.
1.2000
+2.56%
CGON CG Oncology, Inc.
37.74
+1.45%
CGEM Cullinan Therapeutics, Inc.
16.41
+1.05%
ELVN Enliven Therapeutics, Inc.
27.93
+0.40%
GRTX Galera Therapeutics, Inc.
0.0690
0.00%
NAMS NewAmsterdam Pharma Company N.V.
18.72
-1.47%
KROS Keros Therapeutics, Inc.
60.57
+0.30%